The Step-by-Step Guide to Building a Compliant Annual Product Quality Review (APQR) In Pharmaceuticals

Any QA professional in life sciences who has prepared an Annual Product Quality Review knows how demanding the process can be. What should be a structured quality exercise often turns into weeks of pulling information from scattered sources — spreadsheets, emails, binders, and disconnected systems. 

Batch records in one place, deviations in another, stability data somewhere else. By the time everything is finally assembled, the APQR can feel more like an administrative marathon than a meaningful quality review. Yet APQR exists for a very good reason, and when done properly, it becomes one of the most valuable tools in a pharmaceutical quality system. 

This article explains what APQR is, what it is for, how it differs from related terms, the key regulations that govern it, when it must be completed, who owns it, and how to build one step by step.

What Is The Annual Product Quality Review?

The Annual Product Quality Review, commonly abbreviated as APQR, is a yearly, structured review that evaluates a pharmaceutical product's manufacturing performance, quality outcomes, and compliance history over a defined period. 

It is a regulatory requirement for pharmaceutical manufacturers, and it applies to commercialised products, meaning products that are already on the market and being manufactured at commercial scale.

In practical terms, APQR is the process by which a pharmaceutical company looks back at a full year of data for a given product and asks a fundamental set of questions: Is the manufacturing process performing consistently? Are the quality results within acceptable limits? Have there been trends, deviations, or complaints that signal an emerging risk? Are changes or revalidation activities needed? 

The purpose of conducting this review annually is to provide a structured opportunity to turn historical quality data into actionable knowledge, that can be used to strengthen process performance, reduce patient risk, and continuously improve product quality.

APQR, APR, And PQR — Understanding The Differences

Across the pharmaceutical industry, the annual product review requirement is referred to by several different names, and the terminology can be a source of confusion. In US practice, the annual evaluation required by 21 CFR 211.

180(e) has historically been called the Annual Product Review, or APR. In more recent years, many companies and some FDA communications have adopted the term Annual Product Quality Review, or APQR, though the regulation itself does not mandate a specific name.

Product Quality Review, or PQR, is the standard term used across EU GMP, PIC/S, and WHO guidance. Despite the different names, these terms all refer to essentially the same regulatory exercise, a periodic, comprehensive review of a product's quality and process performance. 

For the purposes of this article, APQR and PQR are used interchangeably, as they represent the same concept applied within slightly different regulatory contexts.

The Regulatory Framework Behind APQR

APQR is not a voluntary best practice — It is a formal regulatory requirement under multiple international frameworks, and understanding which regulations apply to a given product or market is essential for building a compliant review.

The foundational US requirement comes from FDA 21 CFR 211.180(e), which establishes the legal obligation for pharmaceutical manufacturers to conduct an annual evaluation of written records for each drug product. This evaluation must cover batch outcomes, complaints, recalls, returns, and investigations, among other elements. 

Although 21 CFR 211.180(e) is the least prescriptive of the major APQR frameworks, FDA inspectors still expect a thorough and meaningful review, and gaps in coverage or depth can lead to observations during inspections.

ICH Q7, published in the year 2000, introduced the concept of the Product Quality Review for Active Pharmaceutical Ingredients, or APIs. This framework later informed the EU GMP PQR requirement, which was formally incorporated into the EU GMP Guide in 2005. 

EU GMP Chapter 1.10 provides the most detailed and structured framework currently available and is widely used as the reference model by manufacturers operating globally. PIC/S and WHO GMP guidance closely align with this EU structure, serving as globally harmonised adaptations that extend the approach to manufacturers in countries outside the EU and US regulatory spheres.

In practice, most multinational pharmaceutical companies design their APQR process to satisfy the most demanding of the applicable frameworks, typically EU GMP Chapter 1.10, so that the same report can satisfy multiple regulatory requirements simultaneously.

When Should The APQR Be Completed?

The APQR must be completed once per year for each commercialised product. Most companies follow one of two approaches when defining the review period. The first is a calendar year approach, in which the review covers January through December and the finalised report is issued by the end of the first quarter of the following year, typically by the end of March. 

The second is a rolling twelve-month approach, which is commonly used for low-volume products or products that were launched mid-year. Under this model, the review period might run from, for example, July 2023 through June 2024, with the final APQR report completed within three months of the period's end, in this case, by the end of September 2024.

The choice between a calendar year and a rolling twelve-month cycle is typically defined in the company's internal APQR standard operating procedure. Whichever approach is used, the critical principle is consistency — the review period should be applied systematically and the completion timeline should be clearly defined and adhered to.

Who Is responsible For APQR compliance?

Ownership of the APQR sits firmly with Quality Assurance. However, preparing a comprehensive and accurate APQR is not something QA can or should do alone. The review draws on data and expertise from across the organisation, and meaningful cross-functional collaboration is essential to producing a review that genuinely reflects the product's performance.

Quality Control contributes analytical testing data, out-of-specification results, and stability outcomes. Manufacturing provides batch records, yield data, and production performance information. Engineering and Validation contribute qualification and revalidation status updates for processes, equipment, cleaning, and analytical methods. 

Regulatory Affairs provides information on the regulatory status of all product variants, including any submissions, approvals, or pending applications across the markets where the product is sold. All of these functions work together to build the data foundation of the APQR, but the final report must be reviewed and approved by a senior Quality Assurance professional before it is submitted to the relevant regulatory authority.

A clear, well-written standard operating procedure that defines each function's responsibilities, the data they are expected to provide, the timelines they must meet, and the sources from which data should be drawn is one of the most important enablers of a smooth APQR process. Without it, the exercise becomes fragmented, inconsistent, and unnecessarily difficult.

APQR Compliance Starts With Getting GMP Right 

See What It Takes To Get GMP Certified Across EU And US 

→ GMP Certification Guide For EU And US Markets

How To Build A Compliant APQR: A Step-By-Step Approach

Step 1 — Gather All Relevant Information

The first step in preparing a robust APQR is to gather all relevant information that reflects the product's quality, process performance, and regulatory status across the entire review period. 

This is typically the longest and most time-consuming phase of the entire process, and for good reason: without complete and accurate data, every subsequent step is compromised. 

It is also essential to collect data from all markets where the product is sold and across all strengths, formats, and presentations, so that the review reflects the product's full commercial footprint rather than a partial picture.

The information required is clearly defined across the major regulatory frameworks — FDA 21 CFR 211.180(e), EU GMP Chapter 1, ICH Q7, PIC/S, and WHO GMP and it spans several categories. The first category covers starting materials, packaging components, and supplier performance, including API quality and traceability, the performance of key suppliers, and any relevant technical or quality agreements in place. 

The second category is product and process performance data, which includes all batches manufactured during the period, both approved and rejected, along with in-process control results, finished product testing data, stability trends, and yield figures including any variability in yields across batches.

The third category covers planned changes made during the review period, including any process or analytical method changes and all change controls raised, approved, or implemented. The fourth category encompasses unplanned events and quality system outcomes, including rework and scrap, deviations, out-of-specification and out-of-trend results, CAPA effectiveness assessments, customer complaints, returned product, and any recalls. 

The fifth and final category is compliance data, which covers the validation and qualification status of processes, equipment, cleaning procedures, and analytical methods, as well as the regulatory status of all product variants across every market where the product is authorised.

Step 2 — Analyse The Information And Turn Data Into Knowledge

Once all the relevant information has been gathered, the next step is to analyse that data thoughtfully and systematically. The objective of this step is not simply to confirm that results fell within specification limits, it is to gain genuine insight into the product and its manufacturing process. Analysis at the APQR level should go beyond pass-or-fail assessments and look for patterns, trends, and signals that might not be visible when individual events are reviewed in isolation.

This means examining whether batch results are clustering near the edges of acceptance limits, whether yield variability is increasing over time, whether certain raw material lots correlate with higher deviation rates, or whether complaint patterns suggest a process or packaging issue that has not yet generated a formal out-of-specification result. Trend analysis across the full twelve-month dataset is the core analytical tool of the APQR, and the quality of the analysis directly determines the quality of the conclusions that follow.

This analytical phase is also where the APQR moves from being a retrospective compliance exercise to being a genuinely prospective quality tool. Well-executed analysis identifies risks before they become failures, enabling manufacturers to make proactive decisions about process improvements, revalidation activities, or changes to control strategies.

Step 3 — Compile The APQR report

Once the data has been gathered and analysed, the findings are organised into a clear, structured APQR report that aligns with the applicable regulations and the company's internal APQR standard operating procedure. The report should present trends, key findings, identified risks, and conclusions in a way that is accessible and meaningful to QA leadership, auditors, and regulators alike.

A complete APQR report typically includes the product name, review year, and a unique APQR reference number, along with the name of the manufacturing site. The body of the report should walk systematically through each of the data categories gathered in step one, presenting the findings clearly using tables, graphs, statistical summaries, or flow charts as appropriate to help communicate trends and results effectively. 

The report should cover a review of all manufactured batches, including batch outcomes and yield data, in-process and finished product testing results, out-of-specification events, stability data and trending, deviation and CAPA summaries, change control activity, complaint and return data, recall history if applicable, validation and qualification status, regulatory affairs status across all markets, and a comparison of conclusions against the previous year's APQR recommendations.

The report should close with a conclusions section that summarises the overall state of the product and process, a recommendations section that sets out any actions to be taken including process improvements, revalidation activities, or specification reviews and a formal approval section capturing the signatures and dates of all reviewers. Supporting data is typically presented in annexures at the end of the document.

Step 4 — Review, Validate, & Approve The Report

Once the APQR report is compiled, it must go through a formal cross-functional review before it is finalised. Typically, this review involves representatives from Quality Assurance, Quality Control, Manufacturing, Engineering and Validation, and Regulatory Affairs. 

The purpose of this step is to confirm that the data presented in the report is accurate and complete, that the analytical conclusions drawn from that data are sound and well-supported, and that the recommendations proposed are appropriate and prioritised correctly.

This review step is also an important opportunity for teams outside QA to engage directly with the APQR, understand the risks and improvement opportunities identified through the analysis, and align on the actions that will be taken in the year ahead. 

When the cross-functional review is done well, the APQR becomes a shared quality document rather than a QA-owned compliance artefact, and that shared ownership significantly increases the likelihood that the recommendations it contains will actually be acted upon. 

Final approval by a senior Quality Assurance professional confirms that the conclusions are sound, the report is complete, and the document is ready to be submitted and acted on.

Why APQR Matters Beyond Regulatory Compliance?

APQR is often perceived primarily as a regulatory obligation, something that must be done to satisfy inspectors and avoid audit findings. While that obligation is real, it only captures a fraction of the value that a well-executed APQR can deliver. 

For manufacturers who approach the process seriously, the APQR becomes one of the most powerful instruments available for understanding and improving product quality.

By aggregating a full year's worth of manufacturing, quality, and compliance data into a single structured review, the APQR creates a level of visibility that no individual quality event review or monthly report can provide. 

It allows manufacturers to identify potential failure areas before they materialise, making it possible to prevent costly out-of-specification investigations and the rework and downtime that typically accompany them. 

Consistent monitoring of control procedures through the APQR helps reduce manufacturing downtime and increase throughput by catching process drift early, before it reaches a level that requires intervention.

A thorough APQR also deepens the organisation's collective understanding of its products and processes. That deeper understanding empowers teams to make better decisions, maintain regulatory commitments more reliably, and engage more effectively with regulators during submissions and inspections. 

Over time, a strong APQR programme reduces the risk of product recalls, protects the manufacturer's reputation, and strengthens the trust that regulators, partners, and patients place in the company's quality culture. 

It also improves communication across functions — bringing regulatory affairs, quality assurance, engineering, and production into regular, structured dialogue about the health of the products they collectively bring to market.

A Strong APQR Programme Needs The Right Quality Infrastructure Behind It 

Here Is How To Migrate To An eQMS Without Disrupting Your Operations 

→ eQMS Migration Guide For Pharma

In Conclusion

The Annual Product Quality Review is far more than a box-ticking exercise. When approached with genuine rigour and cross-functional commitment, it is a yearly opportunity to step back from the day-to-day flow of manufacturing events and take a clear, evidence-based look at how a product and its processes are truly performing. 

It is the mechanism through which historical quality data is transformed into forward-looking knowledge, that guides process improvements, informs revalidation decisions, shapes change control priorities, and ultimately reduces the risk that a quality problem will reach a patient.

Building a compliant APQR requires a structured approach: gathering comprehensive and accurate data from all relevant sources, analysing that data with a genuine focus on trends and risk rather than simple pass-or-fail assessments, compiling the findings into a clearly structured report that tells the product's quality story for the year, and reviewing that report cross-functionally to validate its conclusions and align on the actions that follow. 

Done consistently and done well, the APQR is not an administrative burden, it is one of the most important investments a pharmaceutical manufacturer makes in the sustained quality and safety of its products.

FAQs

FAQ 1: What Is An Annual Product Quality Review (APQR) In Pharmaceuticals?

An Annual Product Quality Review (APQR) is a structured, yearly assessment of a pharmaceutical product’s manufacturing, quality, and compliance performance. It evaluates trends in batch results, deviations, complaints, stability, and other quality-related data to ensure consistent product quality, identify potential risks, and guide process improvements. APQR is a regulatory requirement for all commercialized products and transforms historical data into actionable knowledge, helping companies strengthen processes and reduce patient risk.

FAQ 2: Who Is Responsible For Preparing And Approving The APQR?

Quality Assurance (QA) owns the APQR process and is responsible for its final approval. However, preparing an APQR is a collaborative effort that involves multiple departments. Quality Control provides analytical testing and stability data, Manufacturing shares batch records and production performance information, Engineering and Validation report on equipment and process qualifications, and Regulatory Affairs provides updates on the regulatory status of the product across markets. The final APQR report must be reviewed and approved by senior QA personnel to ensure it is accurate, complete, and compliant with applicable regulations.

FAQ 3: When And How Should An APQR Be Completed?

The APQR must be completed annually for each commercialized product. Companies usually follow either a calendar year approach, covering January through December, or a rolling twelve-month cycle for products launched mid-year or produced in low volumes. Completing an APQR involves four key steps: gathering all relevant information from batch records, deviations, complaints, stability studies, and regulatory data; analysing this data to identify trends, risks, and potential process improvements; compiling a structured report with findings, trends, conclusions, and recommendations; and reviewing and approving the report through a cross-functional process before submission. When done correctly, the APQR not only ensures regulatory compliance but also supports continuous improvement and risk management.